American Pharmacists Association Urges FDA to Put Patient Safety First in Peptide Review
Key Takeaways
- The American Pharmacists Association (APhA) is urging the FDA to prioritize patient safety and scientific evidence as it reviews peptide substances for potential inclusion on the Section 503A Bulks List.
- The organization warned that unregulated online peptide markets expose patients to risks such as contamination, counterfeit products, inaccurate dosing, and adverse health outcomes.
- APhA said it supports continued peptide research but says current evidence is insufficient to justify compounding many of the nominated peptide substances.
The American Pharmacists Association (APhA) is urging the US Food and Drug Administration (FDA) to prioritize patient safety, scientific evidence, and regulatory oversight in its decision-making process, according to comments submitted to the FDA ahead of the Pharmacy Compounding Advisory Committee (PCAC) review
APhA expressed concern over the rapid expansion of unregulated peptide markets, where products are frequently sold online outside established pharmacy and regulatory channels. According to the organization, these products may expose patients to significant risks, including contamination, inaccurate dosing, counterfeit ingredients, and serious adverse health consequences.
"Pharmacists believe in innovation, but innovation must be grounded in science and patient safety," said Brigid Groves, PharmD, MS, vice president of professional affairs at APhA, in a news release. "When patients are turning to unregulated online sources for peptide products of unknown quality, everyone should be concerned."
Peptide Safety, Evidence Remain Central to FDA Review
APhA acknowledged that compounding pharmacists have long played a role in preparing customized therapies, but pointed out that current evidence remains insufficient for pharmacists to confidently counsel patients on many of the peptide substances under review. They cited limited data on efficacy, safety, drug interactions, and long-term outcomes.
Based on the available evidence, APhA said it still supports the FDA's recommendation not to add the nominated peptide substances to the Section 503A Bulks List at this time. The association also called for stronger patient and clinician education, greater collaboration among the FDA, state boards of pharmacy, the United States Pharmacopeia, and pharmacists to strengthen oversight and quality standards, and continued research to better define the safety and effectiveness of peptide therapies before broader compounding access is considered.
Source
American Pharmacists Association press release, July 17, 2026.